Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations

被引：0
|
作者：
Geng, R. [1 ]
Chen, Y. [1 ]
Miao, J. [2 ]
Liu, H. [1 ]
Qin, Y. [1 ]
Han, Z. [1 ]
Li, S. [1 ]
Guan, Y. [2 ]
Wu, H. [3 ]
Zhao, Y. [2 ]
Wang, Y. [1 ]
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Beijing Chao Yang Hosp, Beijing, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Furmonertinib; Stage I NSCLC; Adjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA15.13
引用
收藏
页码：S120 / S121
页数：2
相关论文
共 50 条
  • [21] Adjuvant therapy for high-risk primary and resected metastatic melanoma
    Hersey, P
    INTERNAL MEDICINE JOURNAL, 2003, 33 (1-2) : 33 - 43
  • [22] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
    Liang, W.
    He, Q.
    Li, C.
    Liang, H.
    Cheng, B.
    He, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S732 - S732
  • [23] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
    He, Qihua
    Liu, Jun
    Cai, Xiuyu
    Li, Caichen
    Liang, Hengrui
    Cheng, Bo
    Xia, Xiaojun
    Guo, Minzhang
    Liang, Peng
    Zhong, Ran
    Li, Feng
    Yu, Ziwen
    Zhao, Yi
    Ou, Limin
    Xiong, Shan
    Li, Jianfu
    Zhang, Jianrong
    He, Jianxing
    Liang, Wenhua
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (11) : 4120 - +
  • [24] High Risk Factors and Benefit of Adjuvant Chemotherapy in Surgically Resected Stage IB NoneSmall Cell Lung Cancer
    Elimimian, E.
    Arteta-Bulos, R.
    Liang, H.
    Alley, E.
    Bilani, N.
    Saravia, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S976 - S976
  • [25] Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial
    Ou, Wei
    Li, Ning
    Wang, Bao-Xiao
    Zhu, Teng-Fei
    Shen, Zhi-Lin
    Wang, Tao
    Chang, Wu-Guang
    Chang, Zeng-Hao
    Hu, Xin-Xin
    Pu, Yue
    Ding, Lie -Ming
    Wang, Si-Yu
    ECLINICALMEDICINE, 2023, 57
  • [26] Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC
    Remon, Jordi
    Hendriks, Lizza E. L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 368 - 370
  • [27] The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study
    Eralp, Y.
    Ak, N.
    Yilmazbayhan, D.
    Ozkan, B.
    Ferhatoglu, F.
    Demirkazik, A.
    Sak, S. Dizbay
    Dilege, S.
    Tanju, S.
    Toker, A.
    Bulutay, P.
    Firat, P.
    Mandel, N. Molinas
    Kilickap, S.
    Onder, S.
    Dikmen, E.
    Alan, O.
    Yumuk, P. F.
    Bozkurtlar, E.
    Lacin, T.
    Ozturk, A.
    Kocaturk, C.
    Karapinar, K.
    Urer, N.
    Uluc, B. Oyan
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S892 - S893
  • [28] Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma
    Margulis, Vitaly
    Matin, Surena F.
    Tannir, Nizar
    Tarnboll, Pheroze
    Shen, Yu
    Lozano, Marisa
    Swanson, David A.
    Jonasch, Eric
    Wood, Christopher G.
    UROLOGY, 2009, 73 (02) : 337 - 341
  • [29] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Kosuke Mima
    Nobutomo Miyanari
    Keisuke Kosumi
    Takuya Tajiri
    Kosuke Kanemitsu
    Toru Takematsu
    Mitsuhiro Inoue
    Takao Mizumoto
    Tatsuo Kubota
    Hideo Baba
    International Journal of Clinical Oncology, 2021, 26 : 903 - 912
  • [30] The efficacy of adjuvant chemotherapy for resected high-risk stage II and stage III colorectal cancer in frail patients
    Mima, Kosuke
    Miyanari, Nobutomo
    Kosumi, Keisuke
    Tajiri, Takuya
    Kanemitsu, Kosuke
    Takematsu, Toru
    Inoue, Mitsuhiro
    Mizumoto, Takao
    Kubota, Tatsuo
    Baba, Hideo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (05) : 903 - 912
12345